Further studies are needed to validate the benefit of SGLT2 inhibitors in reducing pneumonia, pneumonia-related mortality, and sepsis in patients with Type 2 diabetes and to clarify their mechanism of action. The gene discussed is SLC5A2; the disease is susceptibility to pneumonia measurement.